Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover

International Journal of Clinical Practice

Volumn 55, Issue 8, 2001, Pages 560-563

  Puri, B K ^a,b   Counsell Ocr, S J ^a,b   Hamilton, G ^a,b   Richardson, A J ^a,b   Horrobin, D F ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Laxdale Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTER DERIVATIVE; ICOSAPENTAENOIC ACID; NICOTINIC ACID; PHOSPHOLIPID;

ADULT; ARTICLE; BRAIN; CASE REPORT; DEPRESSION; DISEASE SEVERITY; DRUG RESPONSE; FLUSHING; HUMAN; LATERAL BRAIN VENTRICLE; LIPID METABOLISM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REMISSION; SKIN TEST; SOCIAL PHOBIA; SUICIDAL BEHAVIOR; SYMPTOM;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN DISEASES; DEPRESSIVE DISORDER; EICOSAPENTAENOIC ACID; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEURONS; NIACIN; PHOSPHOLIPIDS;

EID: 0034760815     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Horrobin DF. The roles of prostaglandins and prolactin in depression, mania and schizophrenia. Postgrad Med J 1977; 53(suppl 4): 160-165.
2. Horrobin DF, Glen AIM, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994; 13: 195-207.
3. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30: 193-208.
4. Horrobin DF. Schizophrenia: the illness that made us human. Med Hypotheses 1998; 50: 269-288.
5. Horrobin DF. Fatty acids, phospholipids and schizophrenia. In: Yehuda S, Mostofsky DI, Eds. Handbook of EFA biology: biochemistry, physiology and behavioral neurtibiology. Totawa, NJ: Humana Press, 1997; 245-256.
6. Edwards RW, Peet M. EFA intake and depression. In: Peet M, Glen I, Horrobin DF, Eds. Phospholipid spectrum disorder in psychiatry. Carnforth: Marius Press, 1999; 211-221.
7. Muldoon MF. Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990; 301: 309-314.
8. Engelberg H. Low serum cholesterol and suicide. Lancer 1992; 339: 727729.
9. Morgan RE, Palinkas LA, Barrett-Connor EL, Wingard DL. Plasma cholesterol and depressive symptoms in older men. Lancet 1993; 341: 75-79.
10. Hibbeln JR. Long-chain polyunsaturated fatty acids in depression and related conditions. In: Peet M, Glen I, Horrobin DF, Eds. Phospholipid spectrum disorder in psychiatry. Carnforth: Marius Press, 1999; 195-210.
11. Smith RS. The macrophage theory of depression. Med Hypotheses 1991:35:298-306.
12. Hibbeln JR, Salem N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 1995; 62: 1-9.
13. Hibbeln JR. Fish consumption and major depression. Lancet 1998; 351: 1213.
14. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatrv 1998:43:315-319.
15. Stoll AL, Severus WE, Freeman MP et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407-412.
16. Puri BK, Counsell SJ. Richardson AJ, Horrobin DF. Eicosapentaenoic acid in treatment-resistant depression. Arch Gen Psychiatry 2001. In press.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn (DSM-IV). Washington, DC: American Psychiatric Association, 1994.
18. Horrobin DF. Niacin flushing, prostaglandin E and evening primrose oil: a possible objective test for monitoring therapy in schizophrenia. Onhomol Psychiatry 1980; 9: 33-34.
19. Horrobin DF. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; 1:936-937.
20. Morrow JD. Awad JA, Gates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992; 98: 812-815.
21. Glen AIM, Cooper SJ, Rybakowski J etal. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukol Essenl Fatty Acids 1996; 55: 9-15.
22. Murrell TW, Taylor WM. The cutaneous reaction to nicotinic acid (niacin)-furiuryl. Arch Dermatol 1959; 79: 93-98.
23. Bydder GM. Detection of small changes to the brain with serial magnetic resonance imaging. Br J Radio! 1995; 68: 1271-1295.
24. Hajnal JV, Saeed N, Soar EJ et al. A registration and interpolation procedure for subvoxel matching of serially acquired MR images. J Comput Assist Tomocr 1995: 19: 289-296.
25. Hajnal JV. Saeed N, Oatridge A et al. Detection of subtle brain changes using subvoxel registration and subtraction of serial MR images. J Comput Assist Tiimogr 1995; 19: 677-691.
26. Pettegrew JW, Keshavan MS, Panchalingam K et a!. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in firstepisode, drug-naive schizophrenics: a pilot study of the dorsal prcfrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 1991; 48: 563-568.
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
28. Ward PE, Sutherland J, Glen EMT, Glen AIM. Niacin skin Hush in schizophrenia: a preliminary report. Schiyiphr Res 1998: 29: 269-274.
29. Puri BK, Hirsch SR, Easton T. Richardson AJ. A volumetric biochemical niacin-flush based index that non-invasively detects fatty acid deficiency in schizophrenia. Prog Neuropsychophannacol Bid Psychiatry 2001. In press.